Peter J. Graham
Net Worth
Last updated:
What is Peter J. Graham net worth?
The estimated net worth of Mr. Peter J. Graham is at least $8,955,351 as of 18 Feb 2021. He owns shares worth $3,020,931 as insider, has earned $224,100 from insider trading and has received compensation worth at least $5,710,320 in Antares Pharma, Inc..
What is the salary of Peter J. Graham?
Mr. Peter J. Graham salary is $634,480 per year as Executive Vice President of HR, Gen. Counsel, Chief Compliance Officer & Corporation Sec. in Antares Pharma, Inc..
How old is Peter J. Graham?
Mr. Peter J. Graham is 58 years old, born in 1967.
What stocks does Peter J. Graham currently own?
As insider, Mr. Peter J. Graham owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Antares Pharma, Inc. (ATRS) | Executive Vice President of HR, Gen. Counsel, Chief Compliance Officer & Corporation Sec. | 540,417 | $5.59 | $3,020,931 |
What does Antares Pharma, Inc. do?
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.
Peter J. Graham insider trading
Antares Pharma, Inc.
Mr. Peter J. Graham has made 2 insider trades between 2016-2021, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 45,000 units of ATRS stock on 18 Feb 2021. As of 18 Feb 2021 he still owns at least 540,417 units of ATRS stock.
Antares Pharma key executives
Antares Pharma, Inc. executives and other stock owners filed with the SEC:
- Mr. Fred M. Powell (64) Executive Vice President & Chief Financial Officer
- Mr. Peter J. Graham (58) Executive Vice President of HR, Gen. Counsel, Chief Compliance Officer & Corporation Sec.
- Mr. Robert F. Apple (59) Chief Executive Officer, Pres & Director